China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
Sep 23, 2025 12:15 HKT |  |
|
HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership
Sep 15, 2025 15:19 HKT |  |
|
AGFA HealthCare Strengthens Market Position in KLAS Enterprise Imaging Report 2025
Sep 11, 2025 04:00 HKT |  |
|
Elevating Imaging, Empowering Flow - AGFA HealthCare at RSNA 2025
Sep 09, 2025 16:00 HKT | |
|
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D
Sep 01, 2025 20:55 HKT |  |
|
Hua Medicine Announces 2025 Interim Results
Aug 28, 2025 17:07 HKT |  |
|
Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation
Aug 26, 2025 20:00 HKT |  |
|
Lepu Biopharma (2157.HK) announces 2025 interim results
Aug 21, 2025 14:38 HKT |  |
|
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
Aug 20, 2025 20:30 HKT |  |
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Aug 19, 2025 15:00 HKT | |
|
Sino Biopharm (1177.HK) Announces 2025 Interim Results
Aug 18, 2025 19:11 HKT |  |
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT | |
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 14, 2025 18:00 HKT | |
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT | |
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 11:27 HKT |  |
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Aug 08, 2025 18:09 HKT | |
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China, as Everest Medicines Accelerates Accessibility and Capacity Efforts
Aug 05, 2025 10:21 HKT | |
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Aug 02, 2025 00:02 HKT | |
|
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 16:00 HKT |  |
|
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 04:00 HKT | |
|